WP1066, another STAT3 inhibitor, blocks nuclear translocation of phosphorylated STAT3 and inhibits STAT3-mediated transcriptional activation; it is currently being evaluated in a Phase II trial for GBM in combination with radiotherapy [262]. This evidence concerns the gene STAT3 and glioblastoma.